Candel Therapeutics Option Alert: Fri $7 Calls Sweep (3) near the Ask: 1440 vs 1720 OI; Earnings 3/27 Before Open [est] 

Candel Therapeutics Option Alert: Fri $7 Calls Sweep (3) near the Ask: 1440 @ $5.2 vs 1720 OI; Earnings 3/27 Before Open [est] Ref=$12.21

Candel Therapeutics 주식 (NASDAQ: CADL)

Candel Therapeutics (NASDAQ:CADL) 주식

CANDEL THERAPEUTICS INC

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

3 Stocks With Strong Fundamentals Analysts Recommend For Long-Term Success

Equities

News

Markets

ADBE

CADL

TSLA

수요일(11일) 미국 증시는 최근의 인플레이션 보고서에 힘입어 낙관적인 분위기를 보였다. 나스닥 100 지수는 1.7% 급등하여 새로운 최고치를 기록했고, S&amp;P 500 지수는 0.8% 상승했다. 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

수요일 주목받은 주식: 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

Stocks Photo by Phongphan on Shutterstock

NVDA

PLTR

미국 주식 시장은 목요일에 하락하며, 다우존스 지수는 1.35% 하락한 38,596.98에 도달했다. NASDAQ와 S&amp;P 500도 각각 1.4% 하락한 16,049.08과 1.23% 하락한 5,147.21을 기록했다. 전체 시장의 하락에도 불구하고, 일부 종목은 소매 트레이더와 투자자들의 주목을 끌었다.



하루 내내 소매 트레이더와 투자자들의 관심을 끌은 주요 주식은 다음과

목요일의 주요 주식: 포드, 캔들 테라퓨틱스, 엔비디아, 팔란티어, 테슬라

Candel Therapeutics Inc

Cadeler AS

<p><a href="https://trumpstruth.org/statuses/31388" title="https://trumpstruth.org/statuses/31388">https://trumpstruth.org/statuses/31388</a></p>


Macro Economic Events

Politics

Global

Economics

General

Donald Trump Posts On Truth Social "I am pleased to announce that Secretary of the Treasury Scott Bessent, Secretary of Commerce Howard Lutnick, and United States Trade Representative, Ambassador Jamieson Greer, will be meeting in London on Monday, June 9, 2025, with Representatives of China, with reference to the Trade Deal. The meeting should go very well..."

<h2 class="wp-block-heading">Key Takeaways:</h2>
<ul class="wp-block-list">
<li>L3Harris Technologies Inc. (NYSE: <a href="https://www.benzinga.com/quote/LHX"><strong>LHX</strong></a>) trades at lower valuation multiples despite delivering steady contract growth and strong positioning in modern defense segments.</li>
</ul>
<ul class="wp-block-list">
<li>Behind the scenes, <strong>LHX</strong> is building strength in areas the market increasingly cares about: space tech, secure communications, and classified defense systems.</li>
</ul>
<ul class="wp-block-list">
<li>With a growing backlog and steady cash flow, it's the kind of stock that quietly builds momentum, until the market eventually catches up.</li>
</ul>
<h2 class="wp-block-heading">A Quiet Climb in a Defensive Sector</h2>
<p>Defense stocks don't always make headlines, until something goes wrong. Over the past year L3Harris Technologies Inc. has been doing what a lot of investors want right now, which is staying steady, delivering results, and building long-term contracts.&nbsp;</p>
<p>As of early June, shares of L3Harris were trading at approximately $242, down around 3.2% year-over-year. That's a modest decline, especially when you consider the broader market chop and the fact that Lockheed Martin (NYSE: <a href="https://www.benzinga.com/quote/LMT"><strong>LMT</strong></a>), a bigger defense peer, gained less than 4% over the same period. From a valuation standpoint, L3Harris is also smaller than both <strong>LMT</strong> and <strong>RTX</strong> (NYSE: <a href="https://www.benzinga.com/quote/RTX"><strong>RTX</strong></a>), with a market cap of roughly $44.87 billion compared to RTX's $185.70 billion.</p>
<p>That size gap might explain why the market still prices <strong>LHX</strong> at a discount, but the fundamentals tell a different story. The company continues to generate solid free cash flow, expand its presence in next-gen battlefield technologies, and build out capabilities in space and missile defense.&nbsp;</p>
<p>For investors looking beyond the headlines, the disconnect between what <strong>LHX</strong> is doing and what it's currently worth might not last forever.</p>
<h2 class="wp-block-heading">Valuation Breakdown: Underrated by the Numbers</h2>
<p>L3Harris doesn't necessarily trade like a market favorite currently, but the numbers suggest that it deserves a closer look. Right now, it has a P/E ratio of 28.71, which lands between Lockheed Martin at 20.60 and RTX Corp. at 40.78. Not the cheapest, not the most expensive, just sitting quietly in the middle.</p>
<p>Its dividend yield comes in at 1.98%, just slightly ahead of <strong>RTX</strong>, and a bit behind <strong>LMT</strong>'s 2.76%. Again, nothing flashy, but it adds to the picture of a company that's stable and returning value to shareholders.</p>
<p>But behind the scenes, <strong>LHX</strong> has made progress. It focused its operations, kept cash flow steady, and moved deeper into areas like electronic warfare, space systems, and next-gen battlefield tech. Investors may still be cautious after past M&amp;A deals or slower revenue growth, but the core business is holding up well.</p>
<p>If the company continues to deliver, the market may have to reprice that story. For now, the stock still looks like it's being overlooked.</p>
<h2 class="wp-block-heading">Where The Growth is Coming From</h2>
<p>L3Harris isn't putting all its weight behind one big program. Instead, it's building momentum across a mix of high-impact defense segments that offer more than just short-term wins.</p>
<h3 class="wp-block-heading">Space and Airborne Systems: A Quiet Momentum</h3>
<p>These systems are one of its fastest-growing areas. The company develops sensors, payloads, and support systems for missions ranging from ISR and missile tracking to weather and navigation. It also works on the ground systems that power satellite communication and defense, plus advanced avionics and electronic warfare tools.</p>
<h3 class="wp-block-heading">Tactical Comms and Classified Wins</h3>
<p>Tactical Communications is another key element. <strong>LHX</strong> delivers <a href="https://www.l3harris.com/all-capabilities/integrated-tactical-communication-systems">integrated systems</a> that help military teams stay connected in the field that's secure, fast, and built for high-pressure environments. Then there's the classified and cyber defense work, much of which doesn't show up in headlines but continues to grow in priority and funding.</p>
<p>In Q1 2025, L3 Harris reported <a href="https://www.reuters.com/business/aerospace-defense/l3harris-forecasts-upbeat-annual-sales-strong-defense-demand-2025-01-30/">$5.52 billion in revenue</a> and raised its cost-saving target to $1.2 billion for the year. Compared to Lockheed Martin's heavier reliance on the F-35 or <strong>RTX</strong>'s commercial aviation exposure, <strong>LHX</strong>'s diversified defense-first model looks well positioned for what's ahead.</p>
<h2 class="wp-block-heading">Short-Term Catalysts: What Could Move the Stock This Year</h2>
<p>L3Harris might not make the loudest headlines, but a few developments could give the stock real momentum this year. First, the <a href="https://comptroller.defense.gov/Budget-Materials/Budget2025/">FY2025 defense budget</a> is leaning heavily into modernization and readiness, two areas where L3Harris already has a strong presence. More funding means more room for the kind of advanced tech the company is building within modern defense segments.</p>
<p>That momentum is already evident when looking at contracts. L3Harris recently picked up a <a href="https://www.l3harris.com/newsroom/press-release/2025/03/us-space-force-selects-l3harris-continue-modernization-space-domain">$90 million deal</a> with the U.S. Space Force to improve space domain awareness, essentially helping the military better detect and track objects in orbit. Additionally, the company landed close to <a href="https://www.ctol.digital/news/l3harris-lands-300-million-us-army-contract-next-gen-battlefield-radios/">$300 million</a> from the Army to deliver mission-critical comms gear as part of the HMS program. Both deals reinforce its role in next-gen defense infrastructure.</p>
<p>By contrast, some of its peers are navigating challenges. Lockheed Martin is still wrestling with F-35 cost issues, and <strong>RTX</strong> remains tied to <a href="https://www.rtx.com/news/news-center/2025/04/22/rtx-reports-q1-2025-results">commercial aerospace</a>, which doesn't have the same insulation from market volatility.</p>
<p>In a defense-heavy environment, <strong>LHX</strong>'s steady contract flow and focus on core military needs could give it a clearer path forward.</p>
<h2 class="wp-block-heading">Long-Term Upside: Space, Security, and Modern Warfare</h2>
<p>L3Harris is busy positioning itself for the future of defense. Instead of relying on one big program, it's spreading its bets across some of the most important areas in modern warfare, space systems, secure communications, and <a href="https://www.l3harris.com/newsroom/press-release/2025/02/l3harris-and-shield-ai-team-breakthrough-autonomy">battlefield technologies that integrate AI</a>.</p>
<h3 class="wp-block-heading">Tracking Global Defense Priorities</h3>
<p>Its strategy lines up with broader U.S. and NATO priorities around modernization and readiness. L3Harris's focus on modern defense tools lines up with the broader defense shift toward modernization, especially in areas getting more funding attention in recent U.S. and NATO strategy updates.</p>
<p>Leadership is also staying confident. In its most recent earnings report, L3Harris reaffirmed its full-year outlook and highlighted its long-term investments in high-margin areas. And because the company generates strong free cash flow and continues to reinvest in core segments, it has the flexibility to keep building for what's next.</p>
<p>In a sector where demand is often tied to cycles and political shifts, <strong>LHX</strong>'s focus on foundational technologies, backed by steady government contracts, gives it a rare kind of staying power.</p>
<h2 class="wp-block-heading">Risks and Headwinds</h2>
<p>L3Harris has a lot going for it, but it's not without challenges. The Aerojet Rocketdyne acquisition is still being absorbed, and like with any big deal, there's always a chance the integration takes longer or costs more than expected.</p>
<p>There's also some margin pressure to watch. Inflation, wage costs, and supply chain friction have been hitting defense contractors across the board, and L3Harris isn't immune. Recent revenue growth has been solid, but not exactly explosive, so any slowdown in contract wins could take the shine off in the short term.</p>
<p>Then there's the bigger picture: L3Harris is closely tied to U.S. and allied defense budgets. If priorities shift or possession gets delayed, something that's been happening more often, some of that steady momentum could stall. None of this breaks the long-term case, but it's worth keeping in mind if you're expecting a quick payoff.</p>
<h2 class="wp-block-heading">Is the Market Mispricing LHX?</h2>
<p>L3Harris is sitting on a strong foundation, playing in the right growth areas like space systems, secure comms, and cyber, and is still trading at a discount to peers.</p>
<p>Investors may be overlooking how well-positioned <strong>LHX</strong> really is. While others lean heavily on one or two flagship programs, L3Harris is quietly building a diversified, future-ready defense portfolio that lines up with where global spending is heading.</p>
<p>If margins stay healthy and contract wins keep coming in, the market may have to rethink how it values this stock. Over the next 12 to 18 months, there's real potential for a rerating.</p>



Long Ideas

SPACE

Travel

Opinion

Signals

Trading Ideas

Why L3Harris Might Be The Most Undervalued Stock in the Defense Sector

<p><strong>Fartcoin </strong>(CRYPTO: FARTCOIN) has defied the broader market downturn with <a href="https://www.benzinga.com/money/fartcoin-price-prediction#:~:text=Maximum%20Prediction%3A%20%242.26,increase%20from%20its%20current%20value.">a 4% gain today</a>, outperforming major meme coins like <strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and <strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>).</p>
<p><strong>What Happened:</strong> Prominent trader Unipcs <a href="https://x.com/theunipcs/status/1930637347474809194">revealed</a> an unrealized PnL of $4.49 million on his Fartcoin holdings, down $1.17 million in three days and $2.64 million in three weeks. </p>
<p>Despite the sharp drawdown, Unipcs remains committed, arguing that Fartcoin is oversold and bearish sentiment is overstretched.</p>
<p>The trader highlighted the emotional and financial volatility behind big PnLs and emphasized the importance of conviction in sticking to a thesis despite drawdowns.</p>
<p>He also <a href="https://x.com/theunipcs/status/1930729013347025323">pointed</a> out the timing of Coinbase's listing announcement, which he believes could be a catalyst, with Robinhood possibly next in line.</p>
<p>Kadense Pengu noted Fartcoin has retraced 50% from local highs after an 8x rally, pulling back to $0.93, which could serve as a key retest level and buying opportunity. </p>
<p>The recent Coinbase listing marks a major milestone, with more CEX listings likely, increasing accessibility for retail investors and amplifying the memetic appeal.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">After explosive 8x move from the lows, $fartcoin has pulled back ~50% from local high<br /><br />Coinbase listing news yesterday.  Likely other major CEX to follow suit.  Onramps growing for normies to participate and be in on the &#39;joke&#39;<br /><br />Pullback to $0.93 as retest may be a good entry <a href="https://t.co/W2AfRF9Joy">pic.twitter.com/W2AfRF9Joy</a></p>
<p>&mdash; Kadense Pengu°&#x2757;&#xFE0F;&#x2757;&#xFE0F;&#x2757;&#xFE0F; (@iamkadense) <a href="https://twitter.com/iamkadense/status/1931034925613875502?ref_src=twsrc%5Etfw">June 6, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1930739419524563199">said</a> the outperformance is undeniable and <a href="https://x.com/AltcoinSherpa/status/1930717550348054848">confirmed</a> opening a long position. </p>
<p>More Crypto Online <a href="https://x.com/Morecryptoonl/status/1930984136421814569">predicts</a> a potential next leg up is in play, targeting the $1.10–$1.428 range as the first key resistance zone to watch.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45777180/fartcoin-slides-10-in-a-day-what-is-going-on">Fartcoin Slides 10% In A Day: What Is Going On?</a></strong></p>
<p><strong>Why It Matters:</strong> Fartcoin's Coinbase roadmap listing has added a new layer of legitimacy and investor attention. </p>
<p>The exchange said the move is part of its effort to boost transparency by sharing assets under consideration. </p>
<p>The news triggered a 52.6% surge in 24-hour trading volume.</p>
<p>Coinglass data shows open interest in the meme coin also saw a sudden spike (+2.2%) after the news. Derivatives trading volume in the meme coin expanded by 31.4%.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/cannabis/25/06/45714033/fartcoin-outgains-dogecoin-shiba-inu-sunday-night-whats-going-on">Fartcoin Outgains Dogecoin, Shiba Inu Sunday Night—What&#8217;s Going On?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Fartcoin Jumps 4% While Dogecoin, Shiba Inu Fall — 'Outperformance Is Undeniable,' Says Trader

<p><strong>ServiceTitan, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) reported mixed first-quarter <a href="https://www.benzinga.com/quote/TTAN/earnings">results on Thursday</a>.</p>
<p>ServiceTitan posted adjusted earnings of 18 cents per share, beating market estimates of 12 cents per share. The company's quarterly sales came in at $215.69 million versus expectations of $208.69 million.</p>
<p>The company raised its FY2026 sales guidance from $895.00 million-$905.00 million to $910.00 million-$920.00 million.</p>
<p>&#8220;The ROI we deliver to our customers continues to be our greatest advantage,&#8221; said Vahe Kuzoyan, Co-Founder and President, &#8220;We&#8217;re building a series of stacking S-curves to put ourselves in a position to deliver transformative customer outcomes, and each of our four primary areas of focus this year are off to a strong start.&#8221;</p>
<p>ServiceTitan shares dipped 7.7% to trade at $105.68 on Friday.</p>
<p>These analysts made changes to their price targets on ServiceTitan following earnings announcement.</p>
<ul class="wp-block-list">
<li>Morgan Stanley analyst Josh Baer maintained ServiceTitan with an Equal-Weight rating and raised the price target from $107 to $109.</li>
<li>Loop Capital analyst Yun Kim maintained the stock with a Hold and raised the price target from $90 to $100.</li>
<li>Needham analyst Scott Berg reiterated ServiceTitan with a Buy and maintained a $140 price target.</li>
</ul>
<p><strong>Considering buying TTAN stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06142113/image-108-1024x602.png" alt="" class="wp-image-941698" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06142113/image-108-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06142113/image-108-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06142113/image-108-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06142113/image-108.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45813240/top-2-energy-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Energy Stocks That May Fall Off A Cliff In Q2</a></strong></li>
</ul>
<p>Photo via Shutterstock</p>


Earnings

Price Target

Analyst Ratings

TTAN

These Analysts Increase Their Forecasts On ServiceTitan After Q1 Results

<p>UBS  analyst David Vogt   maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Neutral and raises the price target from $73 to $78.</p>


CIEN

UBS Maintains Neutral on Ciena, Raises Price Target to $78

CYCU

Cycurion Announces Continued Listing And Trading Of Shares And Warrants On NASDAQ

<p>Abacus Global Management, Inc. ("Abacus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>), a leader in the alternative asset management space, today announced that its Board of Directors has authorized a new $20 million share repurchase program, effective June 5, 2025 for over a period of up to 18 months, as well as recent Form 4 and other employee share purchases totaling over $2 million.</p>


Buybacks

Abacus Global Management Announces New $20M Share Repurchase Program

<p><strong>Brown-Forman Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) reported weaker-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/BF.B/earnings">fiscal 2025 results on Thursday.</a></p>
<p>The spirits maker posted quarterly net sales of $894 million, down 7% from a year ago and 3% lower on an organic basis. The figure missed analyst expectations of $967.39 million. Diluted earnings per share fell 45% to 31 cents, missing the consensus estimate of 34 cents.</p>
<p>Brown-Forman expects a tough operating landscape in fiscal 2026 amid macroeconomic uncertainty, potential new tariffs, and softer non-branded barrel sales. The company projects low-single-digit declines in both organic net sales and operating income, with a tax rate between 21% and 23%. Capital spending is forecast between $125 million and $135 million.</p>
<p>BF.B shares gained 3.1% to trade at $28.08 on Friday.</p>
<p>These analysts made changes to their price targets on Brown-Forman following earnings announcement.</p>
<ul class="wp-block-list">
<li>JP Morgan analyst Andrea Teixeira maintained Brown-Forman with an Underweight rating and lowered the price target from $34 to $28.</li>
<li>Evercore ISI Group analyst Robert Ottenstein maintained the stock with an In-Line rating and lowered the price target from $38 to $30.</li>
<li>RBC Capital analyst Nik Modi maintained Brown-Forman with a Sector Perform and lowered the price target from $44 to $30.</li>
<li>Morgan Stanley analyst Eric Serotta maintained the stock with an Underweight rating and cut the price target from $32 to $29.</li>
<li>Citigroup analyst Filippo Falorni maintained Brown-Forman with a Neutral and lowered the price target from $35 to $28.</li>
</ul>
<p><strong>Considering buying BF.B stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06141025/image-107-1024x609.png" alt="" class="wp-image-941689" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06141025/image-107-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06141025/image-107-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06141025/image-107-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06141025/image-107.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next:</strong></p>
<ul class="wp-block-list">
<li><strong> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45813240/top-2-energy-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Energy Stocks That May Fall Off A Cliff In Q2</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Brown-Forman Analysts Slash Their Forecasts After Weak Q4 Results

<p>Scotiabank  analyst Nick Altmann   maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Sector Outperform and lowers the price target from $80 to $67.</p>


GTLB

Scotiabank Maintains Sector Outperform on GitLab, Lowers Price Target to $67

<p><strong>Vail Resorts Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) reported mixed financial results for the third quarter on <a href="https://www.benzinga.com/quote/mtn/earnings">Thursday after the bell</a>.</p>
<p>Vail Resorts reported third-quarter revenue of $1.29 billion, narrowly missing estimates of $1.3 billion, according to Benzinga Pro. The company reported third-quarter earnings of $10.54 per share, beating estimates of $10.12 per share.</p>
<p>"Results in the quarter reflect the stability provided by our season pass program as Resort net revenue, excluding Crans-Montana, remained consistent with the prior year even as visitation declined 7%," said Rob Katz, CEO of Vail Resorts.</p>
<p>The company expects fiscal 2025 net income attributable to Vail Resorts to be between $264 million and $298 million, and Resort Reported EBITDA for fiscal 2025 to be between $831 million and $851 million.</p>
<p>Vail Resorts shares dipped 3.9% to trade at $149.00 on Friday.</p>
<p>These analysts made changes to their price targets on Vail Resorts following earnings announcement.</p>
<ul class="wp-block-list">
<li>Truist Securities analyst Patrick Scholes maintained Vail Resorts with a Buy and lowered the price target from $247 to $244.</li>
<li>Morgan Stanley analyst Megan Alexander maintained the stock with an Equal-Weight rating and cut the price target from $152 to $146.</li>
<li>Mizuho analyst Ben Chaiken maintained Vail Resorts with an Outperform rating and raised the price target from $215 to $216.</li>
</ul>
<p><strong>Considering buying MTN stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MTN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06140303/image-106-1024x573.png" alt="" class="wp-image-941678" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06140303/image-106-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06140303/image-106-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06140303/image-106-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06140303/image-106.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45813240/top-2-energy-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Energy Stocks That May Fall Off A Cliff In Q2</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


These Analysts Revise Their Forecasts On Vail Resorts After Q3 Results

<p>Scotiabank  analyst Ovais Habib   maintains Orla Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OLA#TSX">OLA</a>) with a Sector Outperform and raises the price target from C$15.5 to C$16.</p>


TSX:OLA

Scotiabank Maintains Sector Outperform on Orla Mining, Raises Price Target to C$16

<p>Deep-pocketed investors have adopted a bullish approach towards Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Mastercard. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $255,135, and 4 are calls, amounting to $112,675.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $530.0 to $660.0 for Mastercard over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Mastercard options trades today is 264.57 with a total volume of 1,113.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Mastercard's big money trades within a strike price range of $530.0 to $660.0 over the last 30 days.</p>
<h3>Mastercard 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232966_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$2.88</td>
<td>$2.73</td>
<td>$2.76</td>
<td>$580.00</td>
<td>$114.1K</td>
<td align="right">49</td>
<td align="right">442</td>
</tr>
<tr>
<td>MA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$1.74</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$575.00</td>
<td>$55.3K</td>
<td align="right">789</td>
<td align="right">342</td>
</tr>
<tr>
<td>MA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$25.1</td>
<td>$24.6</td>
<td>$24.96</td>
<td>$600.00</td>
<td>$49.9K</td>
<td align="right">98</td>
<td align="right">40</td>
</tr>
<tr>
<td>MA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$2.25</td>
<td>$2.15</td>
<td>$2.25</td>
<td>$530.00</td>
<td>$35.7K</td>
<td align="right">501</td>
<td align="right">180</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.0</td>
<td>$17.45</td>
<td>$17.75</td>
<td>$575.00</td>
<td>$30.1K</td>
<td align="right">340</td>
<td align="right">25</td>
</tr>
</tbody>
</table>
</p>
<h3>About Mastercard</h3>
<p>Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.</p>
<p>Having examined the options trading patterns of Mastercard, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Mastercard Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 746,651, the MA's price is up by 0.37%, now at $587.59. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 54 days.</li>
</ul>
<h3>Expert Opinions on Mastercard</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $656.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Mastercard, which currently sits at a price target of $660.<br />
&#x2A; An analyst from Jefferies persists with their Buy rating on Mastercard, maintaining a target price of $655.<br />
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $640.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Mastercard, which currently sits at a price target of $670. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mastercard with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Looking At Mastercard's Recent Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HPE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Hewlett Packard. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 22% bearish. Among these notable options, 2 are puts, totaling $56,530, and 7 are calls, amounting to $729,943.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $17.0 to $22.0 for Hewlett Packard over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Hewlett Packard stands at 6415.0, with a total volume reaching 27,925.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hewlett Packard, situated within the strike price corridor from $17.0 to $22.0, throughout the last 30 days.</p>
<h3>Hewlett Packard Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232962_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$0.8</td>
<td>$0.76</td>
<td>$0.78</td>
<td>$19.00</td>
<td>$312.0K</td>
<td>5.2K</td>
<td>4.5K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.32</td>
<td>$0.29</td>
<td>$0.32</td>
<td>$18.50</td>
<td>$104.1K</td>
<td>12.2K</td>
<td>6.8K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$0.37</td>
<td>$0.35</td>
<td>$0.36</td>
<td>$22.00</td>
<td>$90.0K</td>
<td>8.7K</td>
<td>2.5K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.31</td>
<td>$0.29</td>
<td>$0.31</td>
<td>$18.50</td>
<td>$75.7K</td>
<td>12.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$0.78</td>
<td>$0.67</td>
<td>$0.78</td>
<td>$18.00</td>
<td>$54.2K</td>
<td>8.6K</td>
<td>706</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hewlett Packard</h3>
<p>Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.</p>
<h3>Current Position of Hewlett Packard</h3>
<ul>
<li>With a trading volume of 8,071,142, the price of HPE is up by 0.9%, reaching $17.92.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 89 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Hewlett Packard</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $22.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Raymond James persists with their Strong Buy rating on Hewlett Packard, maintaining a target price of $26.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Hewlett Packard, targeting a price of $24.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Hewlett Packard, targeting a price of $22.<br />
&#x2A; An analyst from Evercore ISI Group upgraded its action to Outperform with a price target of $22.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Hewlett Packard, which currently sits at a price target of $20. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hewlett Packard options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With HPE

<p>High-rolling investors have positioned themselves bullish on Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in RKLB often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 41 options trades for Rocket Lab USA. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 48% bullish and 46% bearish. Among all the options we identified, there was one put, amounting to $39,200, and 40 calls, totaling $3,192,917.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.0 to $45.0 for Rocket Lab USA over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Rocket Lab USA's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Rocket Lab USA's substantial trades, within a strike price spectrum from $1.0 to $45.0 over the preceding 30 days.</p>
<h3>Rocket Lab USA Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232957_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.35</td>
<td>$17.0</td>
<td>$17.35</td>
<td>$10.00</td>
<td>$1.1M</td>
<td>1.1K</td>
<td>694</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.75</td>
<td>$12.4</td>
<td>$12.45</td>
<td>$16.00</td>
<td>$176.7K</td>
<td>558</td>
<td>153</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$30.00</td>
<td>$134.0K</td>
<td>12.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$24.00</td>
<td>$123.0K</td>
<td>3.5K</td>
<td>338</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$39.00</td>
<td>$102.8K</td>
<td>201</td>
<td>278</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rocket Lab USA</h3>
<p>Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.</p>
<p>In light of the recent options history for Rocket Lab USA, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Rocket Lab USA</h3>
<ul>
<li>Trading volume stands at 25,992,237, with RKLB's price up by 8.78%, positioned at $28.77.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>What Analysts Are Saying About Rocket Lab USA</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $29.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Rocket Lab USA, which currently sits at a price target of $32.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $28.<br />
&#x2A; An analyst from Roth Capital persists with their Buy rating on Rocket Lab USA, maintaining a target price of $35.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Rocket Lab USA with a target price of $34.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Neutral rating for Rocket Lab USA, targeting a price of $16. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rocket Lab USA options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


RKLB

Unpacking the Latest Options Trading Trends in Rocket Lab USA

<p>Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $189.0, with a high estimate of $215.00 and a low estimate of $158.00. This current average has decreased by 7.09% from the previous average price target of $203.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232913_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Applied Mat is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$158.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$195.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Applied Mat. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Applied Mat compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Applied Mat's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Applied Mat's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Applied Mat analyst ratings.</strong></a></p>
<h2>Get to Know Applied Mat Better</h2>
<p>Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.</p>
<h3>Applied Mat: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Applied Mat's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.83%</strong> as of 30 April, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Applied Mat's net margin is impressive, surpassing industry averages. With a net margin of <strong>30.1%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Applied Mat's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>11.37%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Applied Mat's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.38%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Applied Mat's debt-to-equity ratio is below the industry average. With a ratio of <b>0.35</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMAT

What Analysts Are Saying About Applied Mat Stock

<p>Across the recent three months, 4 analysts have shared their insights on Niagen Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Niagen Bioscience, revealing an average target of $14.5, a high estimate of $23.00, and a low estimate of $11.00. This current average reflects an increase of 35.9% from the previous average price target of $10.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232901_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Niagen Bioscience. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean McGowan</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Niagen Bioscience. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Niagen Bioscience compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Niagen Bioscience's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Niagen Bioscience's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NAGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Niagen Bioscience analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Niagen Bioscience</h2>
<p>Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.</p>
<h3>Niagen Bioscience: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Niagen Bioscience displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>37.59%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Niagen Bioscience's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.61%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Niagen Bioscience's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.98%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Niagen Bioscience's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>6.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Niagen Bioscience's debt-to-equity ratio is below the industry average at <strong>0.06</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NAGE

What 4 Analyst Ratings Have To Say About Niagen Bioscience

<p>During the last three months, 5 analysts shared their evaluations of MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.8, with a high estimate of $34.00 and a low estimate of $18.00. Marking an increase of 18.58%, the current average surpasses the previous average price target of $22.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232886_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of MP Materials's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$29.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MP Materials. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MP Materials compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of MP Materials's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of MP Materials's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on MP Materials analyst ratings.</strong></a></p>
<h2>Get to Know MP Materials Better</h2>
<p>MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.</p>
<h3>MP Materials's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining MP Materials's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>24.91%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> MP Materials's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-37.24%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-2.17%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MP Materials's ROA excels beyond industry benchmarks, reaching <strong>-0.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> MP Materials's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.88</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: MP Materials In The Eyes Of 5 Experts

<p>Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) has been analyzed by 19 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $112.47, a high estimate of $169.00, and a low estimate of $91.00. Experiencing a 3.91% decline, the current average is now lower than the previous average price target of $117.05. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232878_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Oshkosh by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Gilardi</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$119.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Shlisky</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$111.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$91.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$94.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$97.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oshkosh. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Oshkosh compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Oshkosh's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Oshkosh's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Oshkosh analyst ratings.</strong></a></p>
<h2>Discovering Oshkosh: A Closer Look</h2>
<p>Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.</p>
<h3>Financial Insights: Oshkosh</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Oshkosh's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-9.08%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>4.85%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Oshkosh's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.68%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Oshkosh's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Oshkosh's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.35</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Oshkosh Through 19 Analysts

<p>Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) underwent analysis by 43 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">21</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">5</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $340.98, a high estimate of $550.00, and a low estimate of $19.05. A 8.14% drop is evident in the current average compared to the previous average price target of $371.21. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232867_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Tesla by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$285.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$450.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Mickey Legg</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$307.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$303.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Lowers</td>
<td>Sell</td>
<td>$19.05</td>
<td>$24.86</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$190.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Mickey Legg</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$280.00</td>
<td>$373.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$455.00</td>
<td>$474.00</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$345.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$404.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$120.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Sell</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$404.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$225.00</td>
<td>$259.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tesla. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tesla compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Tesla's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Tesla's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Tesla analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Tesla</h2>
<p>Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and offer a robotaxi service. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.</p>
<h3>Unraveling the Financial Story of Tesla</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Tesla's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-9.23%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Tesla's net margin excels beyond industry benchmarks, reaching <strong>2.12%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Tesla's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.55%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Tesla's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.33%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Tesla's debt-to-equity ratio is below the industry average. With a ratio of <b>0.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


43 Analysts Assess Tesla: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) in the last three months.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Revolve Gr, presenting an average target of $23.9, a high estimate of $30.00, and a low estimate of $19.00. This current average has decreased by 17.9% from the previous average price target of $29.11. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749232852_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Revolve Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Rick Paterson</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lauren Schenk</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Randal Konik</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Revolve Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Revolve Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Revolve Gr's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Revolve Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RVLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Revolve Gr analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Revolve Gr</h2>
<p>The Revolve Group is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the US, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of unique products from emerging fashion brands with less than $10 million in annual sales.</p>
<h3>Financial Milestones: Revolve Gr's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Revolve Gr's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>9.66%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Revolve Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>3.98%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Revolve Gr's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.65%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Revolve Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.71%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Revolve Gr's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RVLV

What 10 Analyst Ratings Have To Say About Revolve Gr

Health Care

Press Releases

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Management

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

DAWN

OSTX

YMAB

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Astria Therapeutics

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Heron Therapeutics

Immutep Limited - American Depositary Shares

Immutep

Inozyme Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

HC Wainwright & Co.

Canaccord Genuity

Citigroup

B of A Securities

BMO Capital

Screenshot 2024-06-13 at 5.29.56 PM

Biotech

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Comments

Candel Therapeutics

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌